Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart surgeons test tiny tissue removal to stop dangerous rhythm after bypass

NCT ID NCT07492901

Disease control Sponsor: Kasr El Aini Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether removing the ligament of Marshall during coronary artery bypass surgery could prevent a common complication: atrial fibrillation. 220 high-risk patients were randomly assigned to get the extra procedure or standard surgery alone. The goal was to see if this simple addition could safely reduce irregular heartbeats in the week after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ligament of Marshall resection (surgical procedure)
What this could lead to
If successful, this simple surgical step during bypass surgery could lower the risk of dangerous heart rhythm problems after the operation, leading to safer recoveries.
What could go wrong
This is a completed trial, but the procedure adds surgical time and risk. It may not work for all patients, and benefits might be small or limited to certain high-risk groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

220 people

The number who actually took part.

Started

Jan 2024

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Adults aged ≥18 years. Scheduled for elective on-pump coronary artery bypass grafting (CABG). Diagnosed with multivessel coronary artery disease or left main disease requiring surgical revascularization according to current guidelines. Classified as high risk for postoperative atrial fibrillation, defined as the presence of at least two of the following: Age ≥65 years Left atrial enlargement (anteroposterior diameter \>40 mm on transthoracic echocardiography) History of paroxysmal atrial fibrillation not requiring long-term anticoagulation Chronic obstructive pulmonary disease requiring regular pharmacological therapy Ability to provide written informed consent. \*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\* Exclusion Criteria: Preoperative atrial fibrillation requiring active treatment or long-term anticoagulation. History of previous cardiac surgery. Severe left ventricular systolic dysfunction (ejection fraction \<30%). Emergency or urgent CABG. Concomitant cardiac procedures (e.g., valve surgery, surgical ablation for atrial fibrillation). Contraindications to anticoagulation or antiarrhythmic therapy. Inability or unwillingness to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac rhythm disease coronary artery disorder atrial fibrillation prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Post operative arrythmia

Contacts and locations

Locations

  • Cairo University

    Cairo, Egypt

  • Kasr Alainy

    Cairo, 02, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.